Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

April 17, 2025

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate

April 11, 2025

Ozuriftamab Vedotin (BA3021), a Conditionally Binding ROR2-ADC in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck: Antitumor Activity Observed Among Patients with Both HPV Related and HPV-Negative Cancers

March 27, 2025

Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)

March 26, 2025

Updated Results from a Study of Evalstotug (BA3071), an Anti–CTLA-4 Conditionally Active Biologic

February 26, 2025

Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC

December 14, 2024

BA3361, a NextGen CAB ADC Targeting Nectin4

November 11, 2024

Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors

November 7, 2024

Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity.

October 11, 2024

Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

September 14, 2024